Revolution Medicines, Inc. RVMD

Revolution Medicines enters this daily file with filings, not fireworks. The named public developments supplied are a run of SEC EDGAR Form 4 filings dated June 18, 2026, and another dated June 17, 2026, alongside the company’s SEC filing index and submissions JSON. The evidence does not name a new drug approval, product launch, commercial sales update, analyst call or price move. The strongest current fact is more basic and more useful: this is a cancer-drug developer whose newest supplied source rail is official filing activity, with the financial weight still coming from the March 31, 2026 quarter.

The company describes itself as pursuing novel, targeted medicines for patients living with cancer. That official issuer language matters because it puts the financial statements in the right frame. RVMD is not being judged here as a mature sales machine. The supplied facts show a business still spending heavily on research and development before the evidence rail shows product revenue. The official site proves the company’s mission and sector focus; it does not, by itself, prove approval status, sales traction or clinical success beyond the wording supplied.

The latest filed financials are blunt. Revenue from contracts with customers was $0 in the 10-K period ending December 31, 2025. For the 10-Q period ending March 31, 2026, Revolution Medicines reported net income loss attributable to parent of $453.8 million, operating income loss of $445.2 million, research and development expense of $344.0 million, diluted earnings per share of negative $2.29 and diluted weighted average shares outstanding of 198.1 million. The same period shows assets of $2.25 billion, liabilities of $753.8 million, stockholders’ equity attributable to parent of $1.50 billion, cash and cash equivalents of $440.9 million, net cash used in operating activities of $354.2 million and payments to acquire property, plant and equipment of $1.5 million.

The source rail supplied here does not include a TradingView route, chart level, volume figure, moving average, market capitalisation, valuation multiple or intraday price action. The market mechanism that can be discussed safely is therefore the filing mechanism: a development-stage oncology equity using public capital markets, official SEC disclosure and clinical research spend to fund a product story that is not yet supported here by contract revenue. The August 2024 sales agreement allowed sales of common stock through TD Cowen with aggregate gross proceeds of up to $500 million, and the February 2026 at-the-market programme allowed sales with aggregate gross proceeds of up to $1 billion.

What changed in the supplied public record is the appearance of fresh Form 4 filings on June 17 and June 18, 2026, after the May 6, 2026 announcement of quarterly financial results. What remains unproved by this rail is just as important: no supplied evidence gives the content of those Form 4 transactions, no supplied evidence gives product revenue, no supplied evidence gives a current chart signal, and no supplied evidence gives guidance, dividend, buyback, approval or sales data. A deeper file would need named clinical, regulatory or commercial disclosures, but this report cannot invent them.